Recent Updates
Recently added Catalysts

olmesartan alone or in combination with hydrochlorothiazide

Phase 3

Essential Hypertension | Small molecule | Cardiovascular |Pfizer, Inc.|Last Updated: Dec 5, 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment410

FDA Designations

No designations recorded

Clinical trial landscape

olmesartan alone or in combination with hydrochlorothiazide · 1 trial · 1 indication

Phase 3 1
NCT00139698Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential HypertensionEssential Hypertension
COMPLETED410 Analytics
PHASE3COMPLETED
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Essential Hypertension
NCT00139698410
Unlock trial analytics

Study Endpoints

Primary Endpoints

Efficacy of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Secondary Endpoints

Safety and tolerability of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
olmesartan alone or in combination with hydrochlorothiazideDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites32

Inclusion Criteria: * Subject has mild to moderate hypertension Exclusion Criteria: * History of secondary hypertension

Countries:ColombiaEcuadorHong KongIndonesiaMalaysiaPhilippinesSingaporeTaiwanThailandTurkey (Türkiye)
Unlock Eligibility Criteria